European Journal of Biomedical and Pharmaceutical Sciences

FORMULATION DEVELOPMENT AND INVITRO EVALUATION OF VILAZODONE SOLID DISPERSIONS

Ch. Anusha*, A. Naganjaneyulu, P. Sreenivasa Prasanna and K. Thejomoorthy

ABSTRACT

Vilazodone is used to treat depression. It is an SSRI (selective serotonin reuptake inhibitor) and partial serotonin receptor agonist. Main disadvantage with Vilazodone is it belongs to BCS class II drug having 25hrs half-life. So to improve its aqueous solubility it has been formulated as solid dispersions. The main aim of present work is to formulate solid dispersions of improve the solubility and rapidly increases bioavailability of and Vilazodone by using HP β Cyclodextrin and β Cyclodextrin to improve patient compliance, improve the solubility and rapidly increases bioavailability of and Vilazodone. Results of prepared solid dispersions of Vilazodone by Solvent Evaporation method and physical mixture were discussed which includes solubility, melting point determination, percentage yield and in vitro dissolution studies. Characterization in solid state was done by various analytical techniques such as FT-IR studies. Finally by comparing all the formulations (SF1-SF6) SF3 containing Vilazodone + HP β cyclodextrin (1:1.5) shows better results by solvent evaporation method at the end of 60 min with drug release of 88.86%, hence it was selected as the best formulation. By compairing the release kinetics studies of best formulation of Vilazodone with zero order and first order we can say that the best formulation follows first order release kinetics studies.

Keywords: Vilazodone, HP ? cyclodextrin, ? Cyclodextrin, solid dispersions, FT-IR.